Fate Therapeutics (FRA:F6T) Short-Term Debt: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F6T Fate Therapeutics Inc FRA:F6T
33 GF Score
Price €2.11
GF Value €0.65
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics Short-Term Debt?

Fate Therapeutics FRA:F6T -7.79% 33 Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:F6T with a GF Score™ of 33/100 and a GF Value™ of €0.65 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Fate Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2026 was €0.00 Mil.

Fate Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Fate Therapeutics Short-Term Debt Related Terms

Fate Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Fate Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fate Therapeutics Short-Term Debt Chart

Fate Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fate Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:F6T
33GF Score
Fate Therapeutics Inc FRA:F6T
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Fate Therapeutics (FRA:F6T) has a Short-Term Debt of €0.00 Mil as of Jun. 2026.
Is Fate Therapeutics' Short-Term Debt too high?
Fate Therapeutics' current Short-Term Debt is €0.00 Mil. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Short-Term Debt compare to IMRX and NWBO?
Fate Therapeutics' Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Fate Therapeutics's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FRA:F6T) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €2.11 — trading 224% above its estimated fair value. The current Short-Term Debt is €0.00 Mil. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Fate Therapeutics (FRA:F6T), the current Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fate Therapeutics (FRA:F6T) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of €2.11 is trading 224% above its estimated GF Value™ of €0.65. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:F6T:

  • Short-Term Debt: €0.00 Mil
  • GF Value™: €0.65 vs. price of €2.11 (224% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the FRA:F6T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fate Therapeutics Business Description

Other Exchanges FATE:USAF6T:Germany
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score

Get the complete analysis for FRA:F6T

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.11
Price
€0.65
GF Value